Major factor affecting the overall demand for Tissue Heart Valves includes aspects such as a high survival rate observed in older adults suffering from valvular diseases and undergoing valve replacement along with an increasing demand for advanced prosthetic mitral valve implantation devices are driving the growth of Tissue Heart Valves market. Abbott, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, Medtronic, and others, are anticipated to impact the Tissue Heart Valves market significantly.
DelveInsight’s Tissue Heart Valves Devices Market Insights and Forecast report provides the current and forecast Tissue Heart Valves Devices market, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Tissue Heart Valves Devices market.
Some of the essential takeaways from the Tissue Heart Valves Devices Market report:
- According to DelveInsight analysis, North America is expected to dominate the overall Tissue Heart Valves Devices market during the forecast period.
- Key Tissue Heart Valves Devices companies proactively working in the market include Abbott, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, Medtronic, Sorin Group (LivaNova PLC), Braile Biomédica, Labcor Laboratórios, Colibri Heart Valve, ON-X LIFE TECHNOLOGIES, INC., JenaValve Technology Inc., TTK Healthcare Limited, Comed BV, Meril Life Sciences Pvt. Ltd., Beijing Balance Medical Technology Co., Venus Medtech, and others.
- As per an estimate by DelveInsight, Global Tissue Heart Valves Devices Market is contemplated to rise at a significant Compound Annual Growth Rate (CAGR) during the forecast period.
- On September 22, 2021, Abbott had announced that FDA approved their Epic Plus tissue valve for patients that were in need of mitral or aortic valve replacement.
- On July 16, 2020, LivaNova had announced the commercial launch of the Perceval Plus Aortic valve in Europe. Due to the launch of such technologically advanced devices, there can be a rise in the growth of the Tissue Heart Valves in the European region.
- On May 13, 2021, FDA approved the Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve (THV) System to replace a diseased heart valve without open-heart surgery.
- On September 17, 2019, the new polymer heart valve was implanted in the first patient. The polymer heart valve was designed by Caltech researchers and is long-lasting, less expensive to manufacture, and was found to be more biocompatible than the options available for patients.
Interested in knowing how the Tissue Heart Valves Devices Market will be growing by 2026? Click to get a snapshot of Tissue Heart Valves Devices Market Analysis
Tissue Heart Valves Devices Overview
The Tissue Heart Valves are similar to the human tissue, however, these are prepared from animal tissues, such as the porcine (pig) or bovine (cow). The Tissue Heart Valves require chemical treatments or a stent/frame for support purposes. The Tissue Heart Valves tend to last for about 10 to 20 years. The patients that are implanted with this device do not require anticoagulation medications.
Tissue Heart Valves Devices Market Insight
The Tissue Heart Valves, also called bioprosthetic valves have several advantages over mechanical valves, which include the avoidance of lifelong warfarin therapy for preventing the development of blood clots. Tissue Heart Valves require chemical treatment for the purpose of protection or a stent/frame for support. They tend to last for about 10 to 20 years. Furthermore, several companies such as Edward Lifesciences offer support to their customers with reimbursement sources that help in assisting with coverage, coding, and reimbursement of the Tissue Heart Valves. Various technological advancements such as the next-generation Tissue Heart Valves are advantageous for repair and remodeling.
In the Tissue Heart Valves device type market segment, the stentless segment is expected to achieve a larger market share during the forecast period. The stentless tissue valves tend to offer advantages over the stented tissue valves such as reduction in the rate of thrombosis, more physiological flow pattern, and superior hemodynamics in comparison to the stented valves.
In terms of revenue share North America currently leads the global market and is expected that it will remain constant during the forecast period. However, the supremacy of North America will be conspicuously challenged by the European market. This domination is observed majorly due to a rise in government funding, improvement in healthcare infrastructure, aging population, several FDA product approval in the Tissue Heart Valve segment, and an increase in healthcare expenditure.
For instance, on September 23, 2021, Abbott’s tissue heart valve had received FDA approval for the purpose of mitral valve replacement. It had approved both the Abbott’s Epic Plus and Epic Plus Supra Stented Tissue Valves for the treatment of aortic or mitral valve diseases. Due to the recent launches of such Tissue Heart Valves, the need and demand for such technologically advanced devices will increase in the market, thereby leading to a rise in the Tissue Heart Valve market.
Increase in product approvals such as the Evolut™ Transcatheter Aortic Valve Implantation (TAVI) system launched by Medtronic on 22 June 2020, for patients with severe native aortic stenosis who are at low risk of surgical mortality.
To get a further understanding of geography-wise Tissue Heart Valves, get a snapshot of the report Tissue Heart Valves market.
Tissue Heart Valves Devices Market Dynamics
Due to an increase observed in technological advancements, favorable reimbursement guidelines, and an increase in healthcare expenditures, there will be several growth opportunities in the Tissue Heart Valves market. Other factors driving the market are the increasing prevalence of heart valve diseases like aortic valve degeneration and aortic stenosis, the rising demand for minimally invasive procedures, and the longer life expectancy of the geriatric population, which are expected to bolster the Tissue Heart Valve market.
The market for Tissue Heart Valves observed a period of moderate growth due to the outbreak of COVID-19, because of the reduced patient visits to hospitals, reduction in diagnosis and operations due to the susceptibility of COVID-19 infection. Almost every country was affected due to the pandemic. Operative treatments, inpatient surgeries, and minimally invasive surgeries were not performed temporarily as the priorities were more inclined towards COVID- 19 patients.
Know more about which MedTech player is set to emerge as the trendsetter @ Key Tissue Heart Valves Devices Companies Analysis
Scope of the Tissue Heart Valves Devices Market Report
- Geography Covered – Global
- Study Period – 2021-2026
- Market Segmentation By Product Type – Aortic Valve, Mitral Valve, Pulmonary Valve, Tricuspid Valve
- Market Segmentation By Type – Stented Tissue Heart Valves, Stentless Tissue Heart Valves
- Market Segmentation By End-User – Hospitals, Ambulatory Surgical Centers, Others
- Market Segmentation By Geography – North America, Europe, Asia-Pacific, and Rest of World
- Major Players in Tissue Heart Valves Devices Market – Abbott (NYSE:ABT), Boston Scientific Corporation (NYSE: BSX), CryoLife (CRY), Edward Lifesciences Corporation (NYSE:EW), Medtronic (MDT:NYSE), Sorin Group (LivaNova PLC), Braile Biomédica and Labcor Laboratórios, Colibri Heart Valve, ON-X LIFE TECHNOLOGIES, INC., JenaValve Technology Inc., TTK Healthcare Limited (NSE: TTKHLTCARE), Comed BV, Meril Life Sciences Pvt. Ltd., Beijing Balance Medical Technology Co., Ltd (688198:CH), Venus Medtech (VMTHF), and others
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Table of Contents
| 1 | Report Introduction |
| 2 | Executive summary |
| 3 | Regulatory and Patent Analysis |
| 4 | Tissue Heart Valves Devices Market Key factors Analysis |
| 5 | Tissue Heart Valves Devices Porter’s Five Forces Analysis |
| 6 | COVID-19 Impact Analysis on Tissue Heart Valves Devices Market |
| 7 | Tissue Heart Valves Devices Market layout |
| 8 | Tissue Heart Valves Devices Global Company Share Analysis – Key 3-5 Companies |
| 9 | Tissue Heart Valves Devices Company and Product Profiles |
| 10 | Project Approach |
| 11 | KOL Views |
| 12 | DelveInsight Capabilities |
| 13 | Disclaimer |
| 14 | About DelveInsight |
Learn more about the report offerings @ Tissue Heart Valves Devices Future Updates
DelveInsight Reports
DelveInsight’s ‘Cardiac Valvulotome Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Cardiac Valvulotome and the historical and forecasted Cardiac Valvulotome market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key Cardiac Valvulotome companies involved such as Braun Melsungen AG, LeMaitre Vascular, Inc., Andramed GmbH, BD., InvaMed, Koven Technology Canada Inc, and others.
Cardiac Resynchronization Therapy Market
DelveInsight’s ‘Cardiac Resynchronization Therapy Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Cardiac Resynchronization Therapy and the historical and forecasted Cardiac Resynchronization Therapy market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key Cardiac Resynchronization Therapy companies involved such as Boston Scientific Corporation, Medtronic, Medico S.p. A, Microport Scientific Corporation, Biotronik, EBR Systems, Abbott, and others.
Cardiac Restoration Systems Market
DelveInsight’s ‘Cardiac Restoration Systems Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Cardiac Restoration Systems and the historical and forecasted Cardiac Restoration Systems market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key Cardiac Restoration Systems companies involved such as Abbott, BioVentrix, CryoLife, Edwards Lifesciences Corporation, NeoChord, XELTIS, and others.
Cardiac Output Monitors Market
DelveInsight’s ‘Cardiac Output Monitors Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Cardiac Output Monitors and the historical and forecasted Cardiac Output Monitors market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key companies involved such as Osypka Medical GmbH, CNSystems Medizintechnik GmbH., Uscom, Deltex Medical Limited, Edward Lifesciences Corporation, ICU Medical, Inc., LiDCO, Baxter., Getinge AB., GE Healthcare (GENERAL ELECTRIC COMPANY), Biotronik, and others.
Cardiac Monitoring Devices Market
Global Cardiac Monitoring Devices Market report delivers an in-depth understanding of Cardiac Monitoring Devices and the historical and forecasted Cardiac Monitoring Devices market trends, market drivers & barriers, unmet needs, and key Cardiac Monitoring Devices companies involved such as Medtronic, Boston Scientific, Abbott Laboratories, GE Healthcare, BIOTRONIK, and Koninklijke Philips, Asahi Kasei Corporation, MicroPort Scientific Corporation, Hill-Rom Holdings, Nihon Kohden, SCHILLER AG, BioTelemetry, BPL Medical Technologies, ACS Diagnostics, and others.
Cardiac Biomarkers Testing Market
Global Cardiac Biomarkers Testing Market was valued at USD 3.25 billion in 2020, growing at a CAGR of 7.76% during the forecast period from 2021 to 2026 to reach USD 5.07 billion by 2026. The report delivers an in-depth understanding of Global Cardiac Biomarkers Testing market trends, market drivers & barriers, unmet needs, and key Cardiac Biomarkers Testing companies involved such as Beckman Coulter, Siemens Healthcare GmbH, Abbott, bioMérieux SA, F. Hoffmann-La Roche Ltd, Thermo Fischer Scientific Inc, Randox Laboratories Ltd, Tosoh Corporation, DIALAB GmbH, CardioGenics Holdings Inc, and others.
Global Cardiac Assist Devices Market was valued at USD 2.55 billion in 2020, growing at a CAGR of 13.70% during the forecast period from 2021 to 2026, to reach USD 5.50 billion by 2026. The report delivers an in-depth understanding of Global Cardiac Assist Devices and the historical and forecasted Global Cardiac Assist Devices market trends, market drivers & barriers, unmet needs, and key Cardiac Assist Devices companies involved such as Abbott Laboratories, Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc, CARMAT, CorWave SA, Medtronic PLC, Terumo Heart, NovaPump GmbH, Getinge AB Balton Ltd, Meril Life Sciences Pvt. Ltd, Thoratec Corporation, and others.
3D Cardiac Mapping System Market
DelveInsight’s ‘3D Cardiac Mapping System Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of 3D Cardiac Mapping System and the historical and forecasted 3D Cardiac Mapping System market trends, globally, which comprises of North America, Europe, APAC, and RoW, market drivers & barriers, unmet needs, and key 3D Cardiac Mapping System companies involved such as Biosense Webster, (Jhonson & Jhonson), Boston Scientific Corporation, Abbott, Kardium, Medtronic, Catheter Robotics, Inc, Lepu Medical, EP Solutions SA, and others.
Browse Through Our Blog Posts
- With advancements in Innovative Technology, Cardiac Monitoring Devices Market is Booming Significantly
- Mapping the Increasing Burden of Heart Failure: What Does it Bring for Healthcare Market Companies?
- What Factors are Shaping the Trends in the Implantable Cardiac Monitors Market?
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact Us
Shruti Thakur
+1(919)321-6187